Aura Biosciences, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Aura Biosciences, Inc. (AURA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $39.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-30
- Aura Biosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $39.90M, a 66.95% increase from fiscal 2024.
- Aura Biosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $23.90M, a 9.13% increase from fiscal 2023.
- Aura Biosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $21.90M, a 30.36% increase from fiscal 2022.
- Aura Biosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $16.80M, a 69.70% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $39.90M 10-K · filed 2026-03-30 |
| 2024-12-31 | $23.90M 10-K · filed 2025-03-24 |
| 2023-12-31 | $21.90M 10-K · filed 2024-03-27 |
| 2022-12-31 | $16.80M 10-K · filed 2023-03-15 |
| 2021-12-31 | $9.90M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |